Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 4, 2013, Pages 284-294

  Rigby, Mark R ^a   DiMeglio, Linda A ^a   Rendell, Marc S ^b   Felner, Eric I ^c   Dostou, Jean M ^d   Gitelman, Stephen E ^e   Patel, Chetanbabu M ^f   Griffin, Kurt J ^f   Tsalikian, Eva ^g   Gottlieb, Peter A ^h   Greenbaum, Carla J ⁱ   Sherry, Nicole A ^j   Moore, Wayne V ^k   Monzavi, Roshanak ^l   Willi, Steven M ^m   Raskin, Philip ⁿ   Moran, Antoinette ^o   Russell, William E ^p   Pinckney, Ashley ^q   Keyes Elstein, Lynette ^q   Howell, Michael ^r   Aggarwal, Sudeepta ^r   Lim, Noha ^r   Phippard, Deborah ^r   Nepom, Gerald T ⁱ   McNamara, James ^s   Ehlers, Mario R ^t   more..

^a INDIANA UNIVERSITY   (United States)

^b Creighton Diabetes Center   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h UNIVERSITY OF COLORADO DENVER   (United States)

ⁱ BENAROYA RESEARCH INSTITUTE   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k CHILDREN S MERCY HOSPITAL   (United States)

^l CHILDREN S HOSPITAL LOS ANGELES   (United States)

^m CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁿ UNIVERSITY OF TEXAS AT DALLAS   (United States)

^o UNIVERSITY OF MINNESOTA   (United States)

^p VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^q Rho Federal Systems Division Inc   (United States)

^r Immune Tolerance Network   (United States)

^s NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^t Immune Tolerance Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; C PEPTIDE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; HYBRID PROTEIN;

ADOLESCENT; ADULT; ALLERGIC REACTION; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNITY; CELL FUNCTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG TARGETING; DRUG USE; EFFECTOR CELL; EPSTEIN BARR VIRUS INFECTION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMMUNOTHERAPY; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; INSULIN TREATMENT; LIVER INJURY; LYMPHOCYTOPENIA; MALE; MEMORY T LYMPHOCYTE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT DURATION; TUBERCULOSIS; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DRUG DELIVERY SYSTEM; DRUG EFFECTS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PROCEDURES; T LYMPHOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOLOGIC MEMORY; MALE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84887621720     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70111-6     Document Type: Article

References (29)

1. Bluestone JA, Herold K, Eisenbarth G Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
2. Steffes MW, Sibley S, Jackson M, Thomas W Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26:832-836.
3. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986, 2:119-124.
4. Cook JJ, Hudson I, Harrison LC, et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 1989, 38:779-783.
5. Chase HP, Butler-Simon N, Garg SK, et al. Cyclosporine A for the treatment of new-onset insulin-dependent diabetes mellitus. Pediatrics 1990, 85:241-245.
6. Chatenoud L Immune therapies of autoimmune diseases: are we approaching a real cure?. Curr Opin Immunol 2006, 18:710-717.
7. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361:2143-2152.
8. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
9. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608.
10. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
11. Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013, published online July 8. 10.2337/db13-0345.
12. Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013, 381:1905-1915.
13. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009, 15:746-749.
14. Chamian F, Lin SL, Lee E, Kikuchi T, et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med 2007, 5:27.
15. Krueger GG Selective targeting of T cell subsets: focus on alefacept-a remittive therapy for psoriasis. Expert Opin Biol Ther 2002, 2:431-441.
16. Gordon KB, Langley RG Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003, 2:624-628.
17. Gottlieb AB, Casale TB, Frankel E, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 2003, 49:816-825.
18. Krueger GG, Ellis CN Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003, 148:784-788.
19. Krueger GG, Callis KP Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003, 49(suppl):S87-S97.
20. Ellis CN, Krueger GG Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001, 345:248-255.
21. Chamian F, Lowes MA, Lin SL, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005, 102:2075-2080.
22. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003, 139:1563-1570.
23. Lachin JM, McGee PL, Greenbaum CJ, et al. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. PloS One 2011, 6:e26471.
24. Astellas Pharma US Voluntary US market discontinuation of amevive (alefacept), (accessed Sept 13, 2013). http://www.amevive.com/Physician%20letter.pdf.
25. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004, 53:426-433.
26. Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012, 61:2066-2073.
27. Gitelman SE, Gottlieb PA, Rigby MR, et al. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: a randomized double-blind phase 2 trial. Lancet Diabetes Endocrinol 2013, published online Aug 28. http://dx.doi.org/10.1016/S2213-8587(13)70065-2.
28. Mordes JP, Bortell R, Doukas J, et al. The BB/Wor rat and the balance hypothesis of autoimmunity. Diabetes Metab Rev 1996, 12:103-109.
29. Bour-Jordan H, Bluestone JA Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009, 229:41-66.